Pourjamal, Negar
Yazdi, Narjes
Halme, Aleksi
Joncour, Vadim Le
Laakkonen, Pirjo
Saharinen, Pipsa
Joensuu, Heikki
Barok, Mark
Funding for this research was provided by:
University of Helsinki
Article History
Received: 14 August 2023
Accepted: 5 February 2024
First Online: 17 February 2024
Declarations
:
: The Committee for animal experiments of the District of Southern Finland approved the animal experiments under the licenses ESAVI/403/2019, ESAVI/11614/2022, and ESAVI/10262/2022. The reporting in the manuscript follows the recommendations in the ARRIVE guidelines (ExternalRef removed).
: Not applicable.
: H. Joensuu has an advisory board relationship at Orion Pharma, Neutron Therapeutics, and Maud Kuistila Foundation, has ownership interest (including patents) at Sartar Therapeutics, has received a honorarium for presentation from Deciphera Pharmaceuticals. M. Barok and H. Joensuu report grants from Mersana Therapeutics, Defense Therapeutics, and Merck KGaA outside the submitted work. No potential conflicts of interest were disclosed by the other authors.